药物性肝损伤（DILI）是西方国家急性肝衰竭（ALF）和肝移植的重要原因。对乙酰氨基酚（APAP）过量是DILI的主要促成因素，导致肝细胞通过坏死死亡，该研究旨在探究Neddylation在DILI在，尤其是APAP过量引起的肝损伤中的作用和机制。

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development ...

本研究研发出 一种堆叠阵列芯片，它由上层的肝脏芯片和下层的巨噬细胞芯片组成。研究人员先将肝细胞与特定混合液滴在肝脏芯片的微柱阵列上，形成3D肝脏微组织。同时，对巨噬细胞进行预处理后，接种到巨噬细胞芯片。然后将两者组装并共培养，设置不同处理组，成功构建了iDILI模型。 该模型细胞活力接近100%，并且确定了诸如血清需求、细胞接种密度等优化参数，在多细胞系和原代细胞中都验证了其可行性。

药物性肝损伤（Drug-induced liver injury,DILI）是临床常见的药物不良反应之一。对乙酰氨基酚(acetaminophen,APAP)又称为扑热息痛，目前较为常用的解热镇痛 ...

This may hint at what lies ahead as we navigate the (mostly erroneous) tendency to identify every cell death process in drug hepatotoxicity and other liver diseases as ferroptosis. DILI is broadly ...

Drug-induced liver injury (DILI) is a significant health concern that arises when medications or supplements cause damage to the liver. This condition can lead to serious complications ...

Using the Liver-on-a-chip hepatic co-culture model (assessed by CN-Bio’s partners at the US FDA), the DILI in vitro Service can screen the gene editing reagents, antibodies, small molecules ...

Drug-induced liver injury (DILI) is common because it can be caused by different pharmacological agents from nearly all classes of medications, including hepatotoxic drugs, anesthetics, anticancer ...

Derisking of drug-induced liver injury (DILI) continues to be a challenge for pharmaceutical scientists. Join Michael Hafey, Principal Scientist at Merck, as he discusses how to utilize a two-tiered ...

However, the liver's robust antioxidant defenses, including glutathione (GSH) and vitamin E, question the widespread applicability of ferroptosis as a primary mode of cell death in DILI.